BioPharma Resources

Drug Trial Radar · NCT07936487

IIIb Trial for RC28-E Injection in Participants With DME and wAMD

An Open-Label, Multicenter, Single-Arm Phase IIIb Clinical Trial to Evaluate the Safety and Tolerability of RC28-E Injection in Participants With Diabetic Macular Edema and Wet Age-Related Macular Degeneration

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

350

Planned (sponsor's estimate)

Start

Oct 30, 2026

Primary completion

Dec 1, 2028

Study completion Jun 30, 2029

Sponsor

Lead sponsor
RemeGen Co., Ltd.Industry
Sponsor type
Industry
First posted
Nov 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to primarily determine the safety profile of RC28-E in participants with DME and wAMD. Also explore the efficacy.

Conditions

  • Diabetic Macular Edema (DME)
  • wAMD

Interventions

  • RC28-EBiological

    Ophthalmic solution for intravitreal injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and Severity of Ocular/ Non-ocular Adverse Event.Time frame: 52 week

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.